Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 4/20 | 0.66 |
| ▸ | GLS2 | Q9UI32 | 4/20 | 0.66 |
| ▸ | MDM2 | Q00987 | 10/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TCF4 | P15884 | 1/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12009058 | 1.00 | GLS (0.66) | GLSGLS2MDM2NPC1RAB9A | |
| SCHEMBL12009040 | 0.93 | GLS (0.56) | GLSGLS2MDM2NPC1RAB9A | |
| SCHEMBL12009746 | 0.90 | GLS (0.53) | GLSGLS2MDM2NPC1RAB9A | |
| SCHEMBL18545539 | 0.89 | MDM2 (0.61) | GLSGLS2MDM2NPC1RAB9A | |
| SCHEMBL13446973 | 0.89 | MDM2 (0.61) | GLSGLS2MDM2NPC1RAB9A | |
| SCHEMBL13464571 | 0.87 | GLS (0.51) | GLSGLS2MDM2NPC1RAB9A | |
| SCHEMBL13446969 | 0.85 | MDM2 (0.60) | GLSGLS2MDM2NPC1RAB9A | |
| SCHEMBL12009065 | 0.81 | MDM2 (0.63) | GLSGLS2MDM2NPC1RAB9A | |
| SCHEMBL18545608 | 0.81 | MDM2 (0.63) | GLSGLS2MDM2NPC1RAB9A | |
| SCHEMBL12009109 | 0.79 | TCF4 (0.70) | GLSMDM2NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170049751-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | DASGUPTA RAMANUJ (US) | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170049751-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | CTNNB1, CTNNA1, CTNNBL1 | GLS 507/4885GLS2 338/4885MDM2 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.